# Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

> **NCT05393791** · PHASE2 · RECRUITING · sponsor: **Leiden University Medical Center** · enrollment: 168 (estimated)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **OTHER:** Patient-specific adaptive therapy
- **DRUG:** Abiraterone acetate
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT05393791
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-10
- **Primary completion:** 2027-11-10
- **Final completion:** 2027-11-10
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393791, "Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05393791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*